Manages moderately severe acute pain. ANDA 217789, held by Caplin Steriles. Ketorolac Tromethamine.
As of Nov 21, 2026, ANDA 217789 (Ketorolac Tromethamine), held by Caplin Steriles, was first approved by FDA on May 10, 2023, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Acute Pain in Adult Patients Ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 10, 2023 | Original application | Approved | None posted |
| Ketorolac Tromethamine15MG/ML · injectable;injection | Ketorolac Tromethamine | Rx |
| Ketorolac Tromethamine30MG/ML · injectable;injection | Ketorolac Tromethamine | Rx |
| Nov 21, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| May 10, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters